{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T18:40:01Z","timestamp":1781030401894,"version":"3.54.1"},"reference-count":124,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2017YFC0907601"],"award-info":[{"award-number":["2017YFC0907601"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-B-013"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/13543784.2024.2312216","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:14:28Z","timestamp":1706692468000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology"],"prefix":"10.1080","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0668-455X","authenticated-orcid":false,"given":"Xingyu","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China"},{"name":"Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-3043","authenticated-orcid":false,"given":"Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China"},{"name":"Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2889","authenticated-orcid":false,"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China"},{"name":"Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3883-2318","authenticated-orcid":false,"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China"},{"name":"State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China"},{"name":"Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205375"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep141"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key329"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66990-5"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.47"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103084"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090734"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel155"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2023-0012"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.02.006"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00634-x"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(88)91282-0"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12673"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.9.1529"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39127"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00932-6"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa367"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2779"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2792"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13138"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13118"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key360"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24662"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2010.29"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0722.2009.00659.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080174"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020272"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841732"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.02.010"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102381"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e39"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2007.02049.x"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22603"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1912"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200738013"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.168"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez052"},{"key":"e_1_3_4_40_1","article-title":"Single-cell RNA sequencing reveals the expansion of cytotoxic CD4+ T lymphocytes and a landscape of immune cells in primary Sj\u00f6gren\u2019s syndrome","volume":"11","author":"Hong X","year":"2021","unstructured":"Hong X, Meng S, Tang D, et al. Single-cell RNA sequencing reveals the expansion of cytotoxic CD4+ T lymphocytes and a landscape of immune cells in primary Sj\u00f6gren\u2019s syndrome. Front Immunol [Internet]. 2021;11. [cited 2023 Oct 1]. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.594658","journal-title":"Front Immunol [Internet]"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.02.012"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04606.x"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217646"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0227-z"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309348234"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.05.005"},{"issue":"126","key":"e_1_3_4_47_1","first-page":"222","article-title":"Blocking T cell co-stimulation in primary Sj\u00f6gren\u2019s syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers","volume":"38","author":"Pontarini E","year":"2020","unstructured":"Pontarini E, Verstappen GM, Grigoriadou S, et al. Blocking T cell co-stimulation in primary Sj\u00f6gren\u2019s syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers. Clin Exp Rheumatol. 2020;38(Suppl 126):222\u2013227.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2006.02.007"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213929"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.110"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200111)44:11<2633:AID-ART443>3.0.CO;2-9"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.05.011"},{"key":"e_1_3_4_54_1","first-page":"1508","article-title":"Hypofunction of the stress axis in Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Johnson EO","year":"1998","unstructured":"Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, et al. Hypofunction of the stress axis in Sj\u00f6gren\u2019s syndrome. J Rheumatol. 1998;25:1508\u20131514.","journal-title":"J Rheumatol"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1366.018"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/0300974023208178882"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41489"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000282"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04354-0"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac167"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222053"},{"key":"e_1_3_4_62_1","first-page":"970","article-title":"Salivary cytokine profiles in primary Sj\u00f6gren\u2019s syndrome differ from those in non-Sj\u00f6gren sicca in terms of TNF-\u03b1 levels and Th-1\/Th-2 ratios","volume":"29","author":"Kang EH","year":"2011","unstructured":"Kang EH, Lee YJ, Hyon JY, et al. Salivary cytokine profiles in primary Sj\u00f6gren\u2019s syndrome differ from those in non-Sj\u00f6gren sicca in terms of TNF-\u03b1 levels and Th-1\/Th-2 ratios. Clin Exp Rheumatol. 2011;29:970\u2013976.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802606778194217"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20299"},{"issue":"1","key":"e_1_3_4_65_1","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren\u2019s syndrome: a pilot study","volume":"31","author":"Zandbelt MM","year":"2004","unstructured":"Zandbelt MM, de WP, van DP, et al. Etanercept in the treatment of patients with primary Sj\u00f6gren\u2019s syndrome: a pilot study. J Rheumatol. 2004;31:96\u2013101. 1","journal-title":"J Rheumatol"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20146"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37874"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077891"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23062"},{"issue":"2","key":"e_1_3_4_70_1","first-page":"126","article-title":"The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases","volume":"28","author":"Aderka D","year":"1992","unstructured":"Aderka D, Engelmann H, Wysenbeek AJ, et al. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr J Med Sci. 1992;28(2):126\u2013130.","journal-title":"Isr J Med Sci"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00015.2002"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-4-5"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.046"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.790741"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.11.003"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224503"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.12.3.291"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214682"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead092"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30160-2"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00122-3"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04724-w"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151955"},{"key":"e_1_3_4_87_1","unstructured":"A phase 2a study of MEDI5872 (AMG557) a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sj\u00f6gren\u2019s syndrome [internet]. ACR Meeting Abstracts. [cited 2023 Oct 4]. Available from: https:\/\/acrabstracts.org\/abstract\/a-phase-2a-study-of-medi5872-amg557-a-fully-human-anti-icos-ligand-monoclonal-antibody-in-patients-with-primary-sjogrens-syndrome\/."},{"key":"e_1_3_4_88_1","unstructured":"Research C for DE and. Efalizumab (marketed as raptiva) information. FDA [Internet]. 2019 [cited 2023 Oct 4]. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/efalizumab-marketed-raptiva-information."},{"key":"e_1_3_4_89_1","unstructured":"Research C for DE and. FDA drug safety communication: safety update on progressive multifocal leukoencephalopathy (PML) associated with tysabri (natalizumab). FDA [Internet]. 2019 [cited 2023 Oct 4]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-safety-update-progressive-multifocal-leukoencephalopathy-pml."},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729901"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40095"},{"key":"e_1_3_4_92_1","unstructured":"Devauchelle-Pensec V Mariette X Jousse-Joulin S et al. Treatment of primary Sj\u00f6gren syndrome with rituximab. Ann Inter Med [Internet]. 2014 [cited 2023 Oct 5]. Available from: https:\/\/www.acpjournals.org\/doi\/10.7326\/M13-1085."},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1146676"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.11.002"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev114"},{"key":"e_1_3_4_97_1","unstructured":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sj\u00f6gren\u2019s syndrome. [cited 2023 Oct 5]. Available from: https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39088."},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222054"},{"key":"e_1_3_4_99_1","unstructured":"Pontarini E Sciacca E Chowdhury F et al. Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy in TRACTISS trial of Sjogren\u2019s syndrome. Arthritis & Rheumatology [Internet]. [cited 2023 Dec 26].Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/art.42772."},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003464"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.817"},{"key":"e_1_3_4_102_1","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita S","year":"2014","unstructured":"De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32:490\u2013494.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev257"},{"issue":"23","key":"e_1_3_4_104_1","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette X","year":"2022","unstructured":"Mariette X, Barone F, Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome. JCI Insight [Internet]. 2022 [cited 2023 Oct 4]; 7(23). Available from: https:\/\/insight.jci.org\/articles\/view\/163030","journal-title":"JCI Insight [Internet]"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02251-0"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead265"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3823"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213036"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41451"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3507"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40513"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2617"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600407"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2157259"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22720"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39859"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.208"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30042-6"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41708"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043694"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206008"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.04.005"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.03.003"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2312216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:37:03Z","timestamp":1727203023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2312216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/13543784.2024.2312216"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2312216","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}